NAPC Defense Inc (BLIS): $BLIS Treasure & Shipwreck Recovery Anno...

$BLIS Treasure & Shipwreck Recovery Announces Operations, Searches

WallStreetSurvivor · 2021-03-10T17:43:27.6600000Z

$BLIS Treasure & Shipwreck Recovery Announces Operations, Searches and Further Discoveries; as well as Video of Operations https://finance.yahoo.com/news/treasure-shipwreck-recovery-announces-operations-130000606.html

Play Episode

8min

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Proactive - Interviews for investors

Bitwise’s Bradley Duke on the BTCG ETP: gold & Bitcoin combined

Bitwise Asset Management European head Bradley Duke talked with Proactive about Bitcoin’s recent price movements and the company’s latest product launch. Duke discussed the volatility of Bitcoin, noting both its tailwinds—such as increased demand from corporate investors and national reserves—and the headwinds, including geopolitical uncertainties. He pointed out that institutional investors are turning instead to alternative safe-haven assets like gold. The conversation then shifted to Bitwise’s latest product, Bitwise Diaman Bitcoin & Gold ETP (BTCG), which launched today on Euronext in Paris and Amsterdam. Duke explained that the product is a collaboration with Diaman Partners, part of asset manager Azimut. The ETP dynamically allocates between Bitcoin and gold based on an index that considers drawdowns and recovery rates. "We’ve looked at the performance of this index versus the S&P 500, Nasdaq 100, and gold alone, and it has outperformed considerably," said Duke. He emphasised that while past performance is no guarantee of future results, the product arrives at a time when institutions are actively seeking alternative safe-haven assets. For more insights and interviews, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for updates. #Bitcoin #Gold #BTCG #Bitwise #CryptoInvesting #DigitalAssets #SafeHaven #ETP #Investment #Markets

Proactive - Interviews for investors

Helium One CEO on historic Tanzania historic licence award; Jackson-31 well flows gas

Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) CEO Lorna Blaisse talked with Proactive's Stephen Gunnion about the latest developments for the company, including a major milestone in Tanzania and updates on its US drilling campaign. Blaisse discussed receiving an offer letter for a mining licence in Tanzania, highlighting its significance as the first of its kind for helium and its larger-than-standard 480 km² coverage. She explained that this will allow Helium One to further appraise the subsurface structure following its Itumbula discovery. The company is currently reviewing the terms, including regulatory requirements and partnerships with the Tanzanian government. On the US front, Blaisse provided updates on the Jackson-31 well in Colorado, confirming free-flowing helium gas with no water association—an important distinction from the Tanzanian project. The rig is now mobilising to drill Jackson-4, part of a broader development campaign that will see multiple wells drilled in the coming weeks. Blaisse also reaffirmed that Blue Star remains on track for helium production in the first half of 2025. With active projects in both Tanzania and the US, Helium One is progressing toward becoming a key helium producer. 📢 For more updates, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications! #HeliumOne #MiningLicense #HeliumExploration #EnergyNews #Tanzania #Colorado #NaturalGas #Investing #ProactiveInvestors

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Followers	0
Posts	3871
Boards Moderated	0
Alias Born	01/18/2021

Volume:	254,655
Day Range:	0.0095 - 0.014
Bid:	0.0096
Ask:	0.014
Last Trade Time:	12:35:50 PM EDT
Total Trades:	6

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BLIS Detailed Quote

Recent BLIS News

More BLIS News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BLIS News

Go Ad-Free